An Assessment With Gillian Woollett, MA, DPhil, Senior Vice President, Avalere Health In this two-part conversation with one of the real go-to experts in the biosimilar field and US regulatory process, we talk with Dr. Woollett about the upcoming transition for insulins and other pharmaceuticals in March 2020, when they become regulated as 351(k) biosimilars. … Continue reading Insulin Transitions: A Dead Zone in the Gap Year, and Other Considerations →